[go: up one dir, main page]

BRPI0924617A8 - Compostos heterociclicos de fenoximetila - Google Patents

Compostos heterociclicos de fenoximetila

Info

Publication number
BRPI0924617A8
BRPI0924617A8 BRPI0924617A BRPI0924617A BRPI0924617A8 BR PI0924617 A8 BRPI0924617 A8 BR PI0924617A8 BR PI0924617 A BRPI0924617 A BR PI0924617A BR PI0924617 A BRPI0924617 A BR PI0924617A BR PI0924617 A8 BRPI0924617 A8 BR PI0924617A8
Authority
BR
Brazil
Prior art keywords
compounds
phenoxymethyl
heterocyclic compounds
phenoxymethyl heterocyclic
phosphodiesterase
Prior art date
Application number
BRPI0924617A
Other languages
English (en)
Inventor
Shapiro Gideon
Ripka Amy
Chesworth Richard
Original Assignee
Envivo Pharmaceuticals Inc
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Envivo Pharmaceuticals Inc, Forum Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of BRPI0924617A2 publication Critical patent/BRPI0924617A2/pt
Publication of BRPI0924617A8 publication Critical patent/BRPI0924617A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS HETEROCÍCLICOS DE FENOXIMETILA Compostos de fenoximetila que inibem pelo menos uma fosfodiesterase 10 são descritos como sendo composições farmacêuticas que contêm esses compostos e métodos para o tratamento de vários distúrbios de SNC por meio da administração de tais compostos a um paciente com necessidade dos mesmos.
BRPI0924617A 2009-05-07 2009-12-18 Compostos heterociclicos de fenoximetila BRPI0924617A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17641309P 2009-05-07 2009-05-07
PCT/US2009/068644 WO2010128995A1 (en) 2009-05-07 2009-12-18 Phenoxymethyl heterocyclic compounds

Publications (2)

Publication Number Publication Date
BRPI0924617A2 BRPI0924617A2 (pt) 2017-07-11
BRPI0924617A8 true BRPI0924617A8 (pt) 2017-10-03

Family

ID=41549054

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924617A BRPI0924617A8 (pt) 2009-05-07 2009-12-18 Compostos heterociclicos de fenoximetila

Country Status (32)

Country Link
US (3) US8343973B2 (pt)
EP (3) EP3020716A1 (pt)
JP (2) JP5628902B2 (pt)
KR (1) KR101662699B1 (pt)
CN (2) CN102459242B (pt)
AU (1) AU2009345802B2 (pt)
BR (1) BRPI0924617A8 (pt)
CA (1) CA2761032A1 (pt)
CL (1) CL2011002792A1 (pt)
CO (1) CO6460744A2 (pt)
CR (1) CR20110648A (pt)
DK (2) DK2427454T3 (pt)
EC (1) ECSP11011479A (pt)
ES (2) ES2409404T3 (pt)
HR (2) HRP20130482T1 (pt)
HU (1) HUE026238T2 (pt)
IL (2) IL216149A (pt)
ME (1) ME02375B (pt)
MX (1) MX2011011755A (pt)
MY (1) MY183910A (pt)
NZ (1) NZ596753A (pt)
PE (1) PE20120900A1 (pt)
PH (1) PH12013501321A1 (pt)
PL (2) PL2617420T3 (pt)
PT (2) PT2617420E (pt)
RS (2) RS54529B1 (pt)
RU (1) RU2531274C2 (pt)
SG (1) SG175900A1 (pt)
SI (2) SI2617420T1 (pt)
SM (2) SMT201300070B (pt)
WO (1) WO2010128995A1 (pt)
ZA (1) ZA201108920B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262241B2 (en) 2008-06-25 2014-05-22 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
BRPI0924617A8 (pt) 2009-05-07 2017-10-03 Envivo Pharmaceuticals Inc Compostos heterociclicos de fenoximetila
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
HK1208681A1 (en) 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259617T3 (es) * 1999-11-05 2006-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Compuestos heterociclicos y su aplicacion como medicamentos.
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1541149A1 (en) 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
RS51385B (sr) 2005-01-07 2011-02-28 Pfizer Products Inc. Heteroaromatična jedinjenja hinolina i njihova upotreba kao pde10 inhibitora
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
AU2009262241B2 (en) * 2008-06-25 2014-05-22 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
BRPI0924617A8 (pt) 2009-05-07 2017-10-03 Envivo Pharmaceuticals Inc Compostos heterociclicos de fenoximetila
BR112012004843A2 (pt) * 2009-09-03 2019-09-24 Allergan Inc compostos como moduladores de tirosina cinase
PT3311666T (pt) * 2010-08-18 2021-06-21 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como ativadores da via de sinalização de catenina

Also Published As

Publication number Publication date
IL216149A (en) 2016-02-29
SG175900A1 (en) 2011-12-29
JP5628902B2 (ja) 2014-11-19
KR101662699B1 (ko) 2016-10-05
SMT201300070B (it) 2013-09-06
SMT201600031B (it) 2016-02-25
HK1186981A1 (en) 2014-03-28
AU2009345802A1 (en) 2011-12-15
JP2015038112A (ja) 2015-02-26
IL244059A0 (en) 2016-04-21
RU2011149637A (ru) 2013-06-20
US20100292238A1 (en) 2010-11-18
SI2617420T1 (sl) 2016-02-29
PT2617420E (pt) 2015-12-18
PE20120900A1 (es) 2012-08-14
WO2010128995A1 (en) 2010-11-11
CO6460744A2 (es) 2012-06-15
ECSP11011479A (es) 2011-12-30
CN102459242B (zh) 2015-08-26
PH12013501321B1 (en) 2014-08-27
ME02375B (me) 2016-06-20
PL2617420T3 (pl) 2016-04-29
EP2617420B1 (en) 2015-09-23
CA2761032A1 (en) 2010-11-11
MX2011011755A (es) 2012-03-16
JP2012526107A (ja) 2012-10-25
PT2427454E (pt) 2013-06-20
PH12013501321A1 (en) 2014-08-27
HK1167402A1 (en) 2012-11-30
ES2409404T3 (es) 2013-06-26
US20150322069A1 (en) 2015-11-12
US8946222B2 (en) 2015-02-03
JP5943053B2 (ja) 2016-06-29
CR20110648A (es) 2012-03-28
KR20120027268A (ko) 2012-03-21
RS54529B1 (sr) 2016-06-30
HRP20151273T1 (hr) 2016-01-29
SI2427454T1 (sl) 2013-08-30
ES2554788T3 (es) 2015-12-23
PL2427454T3 (pl) 2013-09-30
RS52838B (sr) 2013-10-31
CN102459242A (zh) 2012-05-16
DK2427454T3 (da) 2013-06-17
IL216149A0 (en) 2012-01-31
CN105125547A (zh) 2015-12-09
HUE026238T2 (en) 2016-06-28
HRP20130482T1 (en) 2013-08-31
EP2427454A1 (en) 2012-03-14
EP3020716A1 (en) 2016-05-18
CL2011002792A1 (es) 2012-06-01
US20130143888A1 (en) 2013-06-06
DK2617420T3 (da) 2015-12-07
EP2617420A1 (en) 2013-07-24
EP2427454B1 (en) 2013-03-20
ZA201108920B (en) 2012-08-29
US8343973B2 (en) 2013-01-01
RU2531274C2 (ru) 2014-10-20
MY183910A (en) 2021-03-17
BRPI0924617A2 (pt) 2017-07-11
NZ596753A (en) 2013-09-27
AU2009345802B2 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
SV2011003855A (es) Heteroarilos sustituidos
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
BR112015001839A2 (pt) ibrutinibe deuterado
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
UY32312A (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: FORUM PHARMACEUTICALS INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: FORUM PHARMACEUTICALS INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]